Pietro Lampertico

Pietro Lampertico's AcademicInfluence.com Rankings

Pietro Lampertico

Engineering

#4697

World Rank

#5908

Historical Rank

Biomedical Engineering

#313

World Rank

#320

Historical Rank

Applied Physics

#1213

World Rank

#1241

Historical Rank

engineering Degrees

Download Badge

Engineering

Why Is Pietro Lampertico Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Pietro Lampertico's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. (2017) (2984)
EASL Clinical Practice Guidelines: management of chronic hepatitis B. (2009) (1471)
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial (2019) (620)
Epidemiology and surveillance for hepatocellular carcinoma: New trends. (2020) (471)
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review. (2010) (427)
Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell–mediated liver damage (2007) (422)
Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. (2015) (368)
Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. (2007) (333)
Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. (2012) (307)
PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. (2016) (303)
IL-10–Producing Regulatory B Cells in the Pathogenesis of Chronic Hepatitis B Virus Infection (2012) (302)
Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine (2005) (294)
Update of the statements on biology and clinical impact of occult hepatitis b virus infection. (2019) (285)
Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine (2004) (284)
High rates of 30-day mortality in patients with cirrhosis and COVID-19 (2020) (271)
A global scientific strategy to cure hepatitis B. (2019) (253)
Long‐Term suppression of hepatitis B e antigen‐negative chronic hepatitis B by 24‐month interferon therapy (2003) (230)
Prophylaxis and treatment of hepatitis B in immunocompromised patients. (2007) (225)
Targeting mitochondrial dysfunction can restore antiviral activity of exhausted HBV-specific CD8 T cells in chronic hepatitis B (2017) (218)
The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B (2017) (214)
Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. (2016) (211)
A randomized, controlled trial of a 24‐month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum (1997) (184)
Proliferation index as a prognostic marker in breast cancer (1993) (184)
Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. (2019) (178)
Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. (2012) (166)
Thyroid carcinoma—Biologic behavior and mortality: Postmortem findings in 42 cases, including 27 in which the disease was fatal (1966) (162)
IL28B polymorphisms predict interferon‐related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen–negative patients with chronic hepatitis B (2013) (159)
Incidence and predictors of hepatocellular carcinoma in Caucasian chronic hepatitis B patients receiving entecavir or tenofovir. (2015) (147)
Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. (2011) (130)
Entecavir plus tenofovir combination as rescue therapy in pre-treated chronic hepatitis B patients: an international multicenter cohort study. (2012) (125)
Guidance for Design and Endpoints of Clinical Trials in Chronic Hepatitis B—Report From the 2019 EASL‐AASLD HBV Treatment Endpoints Conference (2019) (122)
First-line treatment of chronic hepatitis B with entecavir or tenofovir in ‘real-life’ settings: from clinical trials to clinical practice (2012) (119)
Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B (2012) (118)
High rates of hepatocellular carcinoma in cirrhotic patients with high liver cell proliferative activity (2001) (113)
Natural History of Hepatitis B and C in Renal Allograft Recipients (2005) (112)
Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B. (2017) (104)
TLR7 Agonist Increases Responses of Hepatitis B Virus-Specific T Cells and Natural Killer Cells in Patients With Chronic Hepatitis B Treated With Nucleos(T)Ide Analogues. (2018) (104)
A multicenter randomized controlled trial of recombinant interferon‐α2b in patients with acute transfusion‐associated hepatitis C (1994) (103)
Anti-TNF drugs in patients with hepatitis B or C virus infection: safety and clinical management (2012) (102)
Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. (2019) (100)
Optimal management of hepatitis B virus infection - EASL Special Conference. (2015) (95)
Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. (2013) (94)
Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT (2011) (93)
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis. (2020) (87)
Review article: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients (2016) (86)
Clinical evaluation and applications of the Amplicor HBV Monitor test, a quantitative HBV DNA PCR assay. (1998) (85)
Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine‐resistant mutants (2005) (77)
Dual cut‐off transient elastography to assess liver fibrosis in chronic hepatitis B: a cohort study with internal validation (2011) (76)
Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. (2018) (75)
Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease (2021) (73)
Natural killer cell phenotype modulation and natural killer/T‐cell interplay in nucleos(t)ide analogue‐treated hepatitis e antigen‐negative patients with chronic hepatitis B (2015) (73)
The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. (2015) (71)
Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. (2012) (71)
Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct‐Acting Antivirals for HCV Infection (2019) (69)
Assessing Tumor Angiogenesis (2004) (69)
Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. (2020) (69)
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. (2019) (67)
Serum type III procollagen peptide and laminin (Lam‐P1) detect alcoholic hepatitis in chronic alcohol abusers (1989) (64)
Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. (2020) (63)
[502] ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IS SUPERIOR TO ADEFOVIR MONOTHERAPY FOR LAMIVUDINE-RESISTANT PATIENTS WITH HBeAg-NEGATIVE CHRONIC HEPATITIS B (2007) (62)
Patatin‐like phospholipase domain‐containing 3 I148M affects liver steatosis in patients with chronic hepatitis B (2013) (61)
Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous daa failure. (2019) (60)
Preliminary experience on safety of regorafenib after sorafenib failure in recurrent hepatocellular carcinoma after liver transplantation (2019) (60)
New perspectives in the therapy of chronic hepatitis B (2012) (57)
The clinical and pathogenetic significance of estrogen receptor‐β expression in chronic liver diseases and liver carcinoma (2003) (57)
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. (2020) (57)
The prognosis and management of inactive HBV carriers (2016) (56)
Tenofovir-induced Fanconi syndrome in chronic hepatitis B monoinfected patients that reverted after tenofovir withdrawal. (2014) (56)
Squamous papilloma of upper respiratory epithelium. (1963) (55)
Increased expression of vascular endothelial growth factor in small hepatocellular carcinoma (2007) (52)
Hepatitis B virus long‐term impact of antiviral therapy nucleot(s)ide analogues (NUCs) (2017) (52)
Comparative characterization of B cells specific for HBV nucleocapsid and envelope proteins in patients with chronic hepatitis B. (2019) (50)
Global real‐world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts (2020) (49)
Transient elastography assessment of the liver stiffness dynamics during acute hepatitis B (2010) (48)
Excellent safety and effectiveness of high dose myrcludex-b monotherapy administered for 48 weeks in hdv related compensated cirrhosis: a case report of three patients. (2019) (47)
Lack of Siglec-7 expression identifies a dysfunctional natural killer cell subset associated with liver inflammation and fibrosis in chronic HCV infection (2015) (46)
Sarcopenia is associated with reduced survival in patients with advanced hepatocellular carcinoma undergoing sorafenib treatment (2018) (46)
Non-invasive assessment of liver fibrosis in chronic hepatitis B. (2014) (46)
The Course of Esophageal Varices in Patients with Hepatitis C Cirrhosis Responding to Interferon/ Ribavirin Therapy (2011) (46)
Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals. (2019) (45)
Systematic review with meta‐analysis: do interferon lambda 3 polymorphisms predict the outcome of interferon‐therapy in hepatitis B infection? (2014) (44)
Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H. (2006) (44)
Anaplastic (sarcomatoid) carcinoma of the thyroid gland. (1993) (43)
Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc–positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study (2016) (43)
Performance of Enhanced Liver Fibrosis test and comparison with transient elastography in the identification of liver fibrosis in patients with chronic hepatitis B infection (2013) (43)
Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: a meta-analysis. (2020) (41)
Detection of hepatitis B virus DNA in formalin-fixed, paraffin-embedded liver tissue by the polymerase chain reaction. (1990) (40)
Treatment of hepatitis B: Is there still a role for interferon? (2018) (39)
Health Status of Patients Who Underwent Liver Transplantation During the Coronavirus Outbreak at a Large Center in Milan, Italy (2020) (38)
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B (2007) (36)
Treatment of chronic hepatitis B: update of the recommendations from the 2007 Italian Workshop. (2011) (36)
Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B (2019) (35)
Reactivation of hepatitis B virus during targeted therapies for cancer and immune-mediated disorders (2016) (35)
Drug safety evaluation of adefovir in HBV infection (2011) (35)
Undefined/non-malignant hepatic nodules are associated with early occurrence of HCC in DAA-treated patients with HCV-related cirrhosis. (2020) (34)
Review article: hepatitis C virus infection and type‐2 diabetes mellitus in renal diseases and transplantation (2005) (34)
Detection of hepatitis C virus sequences in liver tissue by the polymerase chain reaction. (1991) (33)
The combination of PIVKA‐II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long‐term oral therapy (2020) (33)
Hepatic Fat—Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs (2020) (33)
Increased detection of antibody to hepatitis C virus in renal transplant patients by third-generation assays. (1996) (32)
Review article: the potential of interferon and nucleos(t)ide analogue combination therapy in chronic hepatitis B infection (2016) (32)
Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. (2017) (31)
Clinical Implications of HBsAg Quantification in Patients with Chronic Hepatitis B (2012) (31)
HBV DNA suppression and HBsAg clearance in HBeAg negative chronic hepatitis B patients on lamivudine therapy for over 5 years. (2012) (30)
Management of hepatocellular carcinoma in the time of COVID-19 (2020) (30)
Natural history and clinical impact of cryoglobulins in chronic hepatitis C: 10-year prospective study of 343 patients. (2007) (29)
Four years of tenofovir monotherapy for NUC naïve field practice European patients suppresses HBV replication in most patients with a favorable renal safety profile but does not prevent HCC in patients with or without cirrhosis (2014) (29)
Development and application of an in vitro model for screening anti‐hepatitis B virus therapeutics (1991) (29)
Partial virological response to nucleos(t)ide analogues in naïve patients with chronic hepatitis B: From guidelines to field practice. (2009) (28)
Less can be more: A finite treatment approach for HBeAg‐negative chronic hepatitis B (2018) (28)
Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy (2014) (28)
Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon (2016) (28)
Assessing long-term treatment efficacy in chronic hepatitis B and C: between evidence and common sense. (2012) (27)
Forecasting Hepatitis C liver disease burden on real‐life data. Does the hidden iceberg matter to reach the elimination goals? (2018) (27)
An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs (2021) (26)
755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS (2013) (26)
Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. (2020) (25)
The nuclear patterns of the cardiac muscle fiber. (1967) (25)
High efficacy of direct‐acting anti‐viral agents in hepatitis C virus‐infected cirrhotic patients with successfully treated hepatocellular carcinoma (2018) (25)
Incidence of liver and non-liver-related outcomes in patients with HCV-cirrhosis after SVR. (2021) (25)
Safety and effectiveness of up to 3 years' bulevirtide monotherapy in patients with HDV-related cirrhosis. (2021) (25)
HBeAg‐negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues (2009) (24)
The Association of Il28b Genotype with the Histological Features of Chronic Hepatitis C Is HCV Genotype Dependent (2013) (24)
Efficacy and safety results of the phase 2 JNJ-56136379 JADE study in patients with chronic hepatitis B: Interim week 24 data (2020) (23)
Antiviral drugs for HBV liver disease (2011) (23)
The times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analog therapy. (2021) (23)
Experience With Early Sorafenib Treatment With mTOR Inhibitors in Hepatocellular Carcinoma Recurring After Liver Transplantation (2020) (23)
High prevalence, low pathogenicity of hepatitis G virus in kidney transplant recipients. (2001) (23)
116 A multicenter italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: A 2-year analysis of 650 patients (2006) (23)
Hepatitis B Virus Infection in the Dialysis Population: Current Perspectives (2008) (22)
The royal wedding in chronic hepatitis B: The haves and the have‐nots for the combination of pegylated interferon and nucleos(t)ide therapy (2015) (22)
Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to IFN and cirrhosis regression (2018) (22)
A baseline tool for predicting response to peginterferon alfa‐2a in HBeAg‐positive patients with chronic hepatitis B (2018) (22)
Recurrence of primary disease in a single lung transplant recipient. (1992) (22)
Utility of ascitic fluid analysis in patients with malignancy-related ascites. (1990) (22)
Optimal therapy of chronic hepatitis B: how do I treat my HBeAg‐negative patients? (2015) (22)
BULEVIRTIDE WITH OR WITHOUT PEGIFNα FOR PATIENTS WITH COMPENSATED CHRONIC HEPATITIS DELTA: FROM CLINICAL TRIALS TO REAL LIFE STUDIES. (2022) (22)
Why do I treat HBeAg‐negative chronic hepatitis B patients with pegylated interferon? (2013) (21)
The use of molecular assays in the management of viral hepatitis. (2008) (21)
Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations (2016) (21)
HEALTH STATUS OF LIVER TRANSPLANTED PATIENTS DURING THE CORONAVIRUS OUTBREAK IN ITALY: A LARGE SINGLE CENTER EXPERIENCE FROM MILAN (2020) (20)
An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. (2021) (20)
Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy (2021) (20)
Hepatitis B virus precore mutants in HBeAg carriers with chronic hepatitis treated with interferon (1995) (19)
Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. (2017) (19)
Add‐on peginterferon alfa‐2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen‐negative chronic hepatitis B genotype D (2018) (19)
85 Five years of sequential LAM TO LAM+ADV therapy suppresses HBV replication in most HBeAg-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma (2006) (19)
98 EXTENDED (2 YEARS) TREATMENT WITH PEGINTERFERON ALFA-2A [40KD] IMPROVES SUSTAINED RESPONSE RATES IN GENOTYPE D PATIENTS WITH HBEAG NEGATIVE CHRONIC HEPATITIS B (2010) (18)
Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy. (2020) (18)
Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update (2021) (17)
OC.09.2: MAINTAINED LONG-TERM SUPPRESSION OF HBV REPLICATION IN NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH ETV MONOTHERAPY IN FIELD PRACTICE: THE ITALIAN MULTICENTER EXPERIENCE (2011) (17)
A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B (2018) (17)
S1179 Bulevirtide Monotherapy at Low and High Dose in Patients With Chronic Hepatitis Delta: 24-Week Interim Data of the Phase 3 MYR301 Study (2022) (16)
Oral antiviral therapy for HBeAg negative chronic hepatitis B: better stop or continue? (2014) (16)
Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes (2020) (16)
Long-Term Lamivudine Monotherapy in Renal-Transplant Recipients with Hepatitis-B-Related Cirrhosis (2005) (16)
X chromosome contribution to the genetic architecture of primary biliary cholangitis. (2021) (16)
Probability-Based Interpretation of Liver Stiffness Measurement in Untreated Chronic Hepatitis B Patients (2015) (15)
Long-term evolution of anti-HCV-positive renal transplant recipients. (1998) (15)
Evaluation of three "beyond Baveno VI" criteria to safely spare endoscopies in compensated advanced chronic liver disease. (2019) (15)
Long-term add-on therapy with adefovir in lamivudine-resistant kidney graft recipients with chronic hepatitis B. (2011) (15)
Endo‐therapies for biliary duct‐to‐duct anastomotic stricture after liver transplantation: Outcomes of a nationwide survey (2019) (15)
Comparison of three therapeutic regimens for genotype‐3 hepatitis C virus infection in a large real‐life multicentre cohort (2020) (15)
Residual risk of HCC during long-term oral nucleos(t)ide analogues (NUCs) in patients with CHB - Is one NUC better than the other? (2019) (15)
Studies of IL28B genotype and response to peginterferon in chronic hepatitis B should be stratified by HBV genotype (2013) (15)
The course of inactive hepatitis B in hepatitis-C-coinfected patients treated with interferon and ribavirin. (2009) (15)
Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions? (2018) (15)
PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history (2013) (14)
The relationship between liver histology and thyroid function tests in patients with non-alcoholic fatty liver disease (NAFLD) (2021) (14)
Views on stopping nucleos(t)ide analogue therapy in patients with chronic hepatitis B. (2020) (13)
COVID-19 Vaccine Acceptance among Liver Transplant Recipients (2021) (13)
Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study (2019) (13)
Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study (2019) (13)
Entecavir versus lamivudine for HBeAg positive and negative chronic hepatitis B. (2006) (13)
HIGH RISK OF RENAL IMPAIRMENT DURING LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IN PATIENTS WITH LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B (2009) (13)
Incremental value of HBcrAg to classify 1582 HBeAg‐negative individuals in chronic infection without liver disease or hepatitis (2021) (13)
Treatment of HBeAg‐negative chronic hepatitis B with pegylated interferon (2011) (12)
Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study (2022) (12)
ORAL COMMUNICATIONSOC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE (2012) (12)
Hepatotropic viruses: new insights in pathogenesis and treatment. (2008) (12)
P1075 PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF) (2014) (12)
Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation: A Retrospective Study (2021) (11)
Real-life effectiveness and safety of Glecaprevir/Pibrentasvir among 723 Italian patients with chronic hepatitis C: The Navigator-II study (2018) (11)
GS-03-Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C patients: Integrated analysis of 12 clinical practice cohorts (2019) (11)
Multicentre randomised controlled trial of recombinant interferon alfa-2b in patients with acute non-A, non-B/type C hepatitis after transfusion. (1993) (11)
High rate of sustained virological response with direct‐acting antivirals in haemophiliacs with HCV infection: A multicenter study (2019) (11)
930 HIGH RISK OF RENAL IMPAIRMENT DURING LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY IN PATIENTS WITH LAMIVUDINE-RESISTANT CHRONIC HEPATITIS B (2009) (11)
HBV and HCV Therapy (2009) (11)
Five years of sequential lam to lam_adv therapy suppresses HBV replication in most hbeag-negative cirrhotics, preventing decompensation but not hepatocellular carcinoma (2005) (11)
T-8 Entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment (2012) (10)
Suppressive effects of tenofovir disoproxil fumarate, an antiretroviral prodrug, on mineralization and type II and type III sodium‐dependent phosphate transporters expression in primary human osteoblasts (2018) (10)
Minimal increases of serum alpha‐foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long‐term oral therapy (2019) (10)
Resistance analysis and treatment outcomes in hepatitis C virus genotype 3‐infected patients within the Italian network VIRONET‐C (2021) (10)
522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDY (2012) (10)
Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. (2019) (10)
IFNL4 rs368234815 and rs117648444 variants predict off‐treatment HBsAg seroclearance in IFN‐treated HBeAg‐negative chronic hepatitis B patients (2018) (9)
P.1.48: EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC HEPATITIS B (2011) (9)
Treatment of chronic hepatitis B: Update of the recommendations from the 2007 (2011) (9)
IFN-free DAA treatment of cirrhotic HCV patients with or without history of HCC: A multicenter prospective trial in Italy (2018) (9)
IS TENOFOVIR SUPERIOR THAN ENTECAVIR IN REDUCING THE RISK OF HEPATOCELLULAR CARCINOMA IN CHRONIC HEPATITIS B? THE CONTROVERSY CONTINUES. (2019) (9)
ENTECAVIR AND TENOFOVIR COMBINATION THERAPY IN CHRONIC HEPATITIS B : RESCUE THERAPY IN PATIENTS WITH ADVANCED FIBROSIS AND MULTIPLE PREVIOUS TREATMENT FAILURES. RESULTS FROM AN INTERNATIONAL MULTICENTER COHORT STUDY (2009) (9)
F.N.16 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBeAg-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS (2010) (9)
Pathology of the thyroid gland in Italy: final remarks. (1982) (9)
Prothrombin induced by vitamin K absence or antagonist‐II and alpha foetoprotein to predict development of hepatocellular carcinoma in Caucasian patients with hepatitis C‐related cirrhosis treated with direct‐acting antiviral agents (2021) (9)
Real life experiences in HCV management in 2018 (2019) (9)
A prospective study of blood alpha‐fetoprotein messenger RNA as a predictor of hepatocellular carcinoma in patients with cirrhosis (2003) (9)
Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis (2020) (9)
Impact of hepatitis C virus and direct acting antivirals on kidney recipients: a retrospective study (2019) (9)
Hepatitis B Virus Reactivation Associated with New Classes of Immunosuppressants and Immunomodulators: A Systematic Review, Meta-analysis, and Expert Opinion. (2022) (8)
Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir (2019) (8)
TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct‐acting antivirals (2019) (8)
Add-On Peginterferon Alfa-2a Significantly Reduces HBsAg Levels in HBeAg-Negative, Genotype D Chronic Hepatitis B Patients Fully Suppressed on Nucleot(s)ide Analogues Treatment: Final Results of the Hermes Study (2016) (8)
Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. (2019) (8)
1010 OPTIB – A MULTICENTER PROSPECTIVE OPEN LABEL STUDY ON TENOFOVIR (TDF) FOR CHRONIC HEPATITIS B PATIENTS WITH SUBOPTIMAL RESPONSE TO ADV OR ADV/LAM TREATMENT (2010) (8)
Low rates of genotypic resistance to adefovir in lamivudine resistant patients treated with adefovir-lamivudine combination therapy for 3 years (2006) (8)
Reply to: Correspondence on 'the times they are a-changing - A refined proposal for finite HBV nucleos(t)ide analogue therapy.' (2021) (8)
Procoagulant imbalance influences cardiovascular and liver damage in chronic hepatitis C independently of steatosis (2019) (8)
Implementation of HCV screening in the 1969–1989 birth‐cohort undergoing COVID‐19 vaccination (2022) (8)
Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals (2021) (7)
EFFECTIVENESS OF ENTECAVIR FOR THE TREATMENT OF NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS: A LARGE MULTICENTER COHORT STUDY IN CLINICAL PRACTICE (2009) (7)
696 ADD ON ADEFOVIR PREVENTS THE EMERGENCE OF ADV RESISTANCE IN LAMIVUDINE-RESISTANT PATIENTS: A 4-YEAR STUDY (2008) (7)
Add-on PEG-IFN improves HBsAg kinetics in patients long-term fully suppressed by nucleos(t)ide analogs (2012) (7)
Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19” (2020) (7)
Reply to: Correspondence on “High rates of 30-day mortality in patients with cirrhosis and COVID-19” (2020) (7)
731 EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B (2011) (7)
Detection of the hepatitis B virus major pre-core mutation by the amplification refractory mutation system technique. (1993) (7)
[Lymphoma of the prostate: case reports and subject review]. (1990) (7)
Tenofovir monotherapy for naive patients with chronic hepatitis B: a multicenter European study in clinical practice in 302 patients followed for 30 months (2012) (7)
Screening of oesophagogastric varices in virus-related compensated advanced chronic liver disease: Beyond the Baveno VI criteria (2017) (7)
1009 EFFECTIVENESS OF ENTECAVIR FOR NUC-NAIVE, HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: A 2-YEAR MULTICENTER COHORT STUDY IN 311 PATIENTS (2010) (7)
Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports (2017) (7)
Pulmonary Resection for Metastasis of Hepatocellular Carcinoma Recurring After Liver Transplant: An Italian Multicenter Experience (2020) (7)
14 A DRUG TRANSPORTER GENE POLYMORPHISM PREDICTS RENAL TUBULAR TOXICITY IN PATIENTS WITH CHRONIC HEPATITIS B ON LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION (2010) (7)
Impact of HBeAg on Hepatocellular Carcinoma Risk During Oral Antiviral Treatment in Patients with Chronic Hepatitis B. (2021) (7)
T-9 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice (2012) (7)
Results of treatment of chronic hepatitis B with pegylated interferon. (2013) (6)
44 The long-term outcome of HBeAg-Negative patients with cirrhosis treated with lamivudine monotherapy: A 5-year prospective cohort study (2004) (6)
399 PNPLA3 I148M AFFECTS LIVER STEATOSIS IN PATIENTS WITH CHRONIC HEPATITIS B (2013) (6)
The use of individual patient-level data (IPD) to quantify the impact of pretreatment predictors of response to treatment in chronic hepatitis B patients (2013) (6)
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts (2021) (6)
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms (2019) (6)
525 TENOFOVIR MONOTHERAPY FOR NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE IN 302 PATIENTS FOLLOWED FOR 30 MONTHS (2012) (6)
Direct detection of HBV preC mutants in heterogeneous viral populations by a modified DNA sequencing method. (1993) (6)
T-12 Tenofovir suppressed viral suppression in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study (2013) (6)
PERSISTENT TRUNCUS ARTERIOSUS COMMUNIS. REVIEW OF THE LITERATURE AND PRESENTATION OF 49 CASES OF TRUE TRUNCUS ARTERIOSUS AND 18 EXAMPLES OF RELATED CONDITIONS. (1964) (6)
Patient-Reported Symptoms and Sequelae 12 Months After COVID-19 in Hospitalized Adults: A Multicenter Long-Term Follow-Up Study (2022) (6)
Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long‐term analogue therapy for hepatitis B (2018) (6)
Maintained viral suppression and excellent safety profile of entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B : a 4-year field practice, multicenter study (2012) (6)
Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data (2022) (6)
HBeAg‐negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues? (2014) (6)
Preprocedural prophylaxis with blood products in patients with cirrhosis: Results from a survey of the Italian association for the study of the liver (AISF). (2022) (6)
High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis (2018) (6)
Does interferon therapy prevent hepatocellular carcinoma in patients with chronic viral hepatitis? (2011) (6)
JNJ‐4178 (AL‐335, Odalasvir, and Simeprevir) for 6 or 8 Weeks in Hepatitis C Virus‐Infected Patients Without Cirrhosis: OMEGA‐1 (2019) (6)
Acute hepatitis following assumption of a herbal remedy. (2008) (6)
18 DRUG TRANSPORTER GENE POLYMORPHISM PREDICTS RENAL TUBULAR TOXICITY IN PATIENTS WITH CHRONIC HEPATITIS B ON LONG-TERM ADEFOVIR AND LAMIVUDINE COMBINATION (2010) (6)
Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. (2020) (6)
Oral antiviral therapy for hepatitis B: the case of besifovir, a new kid on the block with a long way to go (2013) (6)
Discontinuation of nucleoside analogues in hepatitis B virus infection. (2013) (6)
P0641 : Excellent 5-year survival in caucasian chronic hepatitis B (CHB) patients with or without cirrhosis under long-term entecavir (ETV) or tenofovir (TDF) therapy and the impact of hepatocellular carcinoma (HCC) (2015) (6)
11 Adefovir dipivoxil 10 MG (ADV) for the treatment of chronic hepatitis B in patients pre-liver transplantation with lamivudine-resistant patients (2003) (6)
Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data (2019) (5)
F-33 High prevalence of reduced bone mineral density in patients with chronic hepatitis B under nucleos(t)ides analogues treatment (2011) (5)
Adenomatoid tumor of the male genital tract: report of three cases, one associated with adrenal cortical rest. (1981) (5)
Novel Therapies That May Cure Chronic Hepatitis B Virus. (2021) (5)
The importance of baseline viral load when assessing relative efficacy in treatment-naïve HBeAg-positive chronic hepatitis B: a systematic review and network meta-analysis (2014) (5)
Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir (2021) (5)
Immunosuppressive and antiviral treatment of hepatitis C virus–associated glomerular disease: A long-term follow-up (2018) (5)
523 ADD-ON PEG-IFN IMPROVES HBSAG KINETICS IN PATIENTS LONG-TERM FULLY SUPPRESSED BY NUCLEOS(T)IDE ANALOGS (2012) (5)
Six years of “on demand” LAM ± ADV combination therapy significantly reduces the development and progression of esophageal varices in patients with HBeAg-negative cirrhosis (2007) (5)
[496] SIX YEARS OF ON DEMAND LAM±ADV COMBINATION THERAPY SIGNIFICANTLY REDUCES THE DEVELOPMENT AND PROGRESSION OF ESOPHAGEAL VARICES IN PATIENTS WITH HBeAg-NEGATIVE CIRRHOSIS (2007) (5)
The Role of Spleen and Liver Elastography and Color-Doppler Ultrasound in the Assessment of Transjugular Intrahepatic Portosystemic Shunt Function. (2020) (5)
Decompensated Cirrhosis and Sickle Cell Disease: Case Reports and Review of the Literature (2017) (5)
Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC (2021) (5)
Partial Response to Entecavir and Tenofovir in Naïve Patients with Chronic Hepatitis B: Clinical Relevance and Management (2012) (5)
Preprocedural prophylaxis with blood products in patients with cirrhosis: results from a survey of the Italian Association for the study of the Liver (AISF) (2022) (5)
[Clinico-pathologic considerations on 9,952 appendices removed at the Busto Arsizio Hospital from 1966 to 1989]. (1990) (5)
Efficacy and safety of finite 48-week treatment with the siRNA JNJ-3989 and the capsid assembly modulator (CAM-N) JNJ-6379 in HBeAg negative virologically suppressed (VS) chronic hepatitis B (CHB) patients: results from REEF-2 study (2022) (5)
A Genotype-Specific Baseline Score to Predict Response at 48 Weeks Post-Treatment to Peginterferon Alfa-2a in Patients with HBeAg-Negative Chronic Hepatitis B (2016) (5)
Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study (2020) (5)
730 PEGBELIVER STUDY: HBSAG DECLINE AT WEEK 24 OF EXTENDED PEGINTERFERON ALFA-2A (PEG-IFNα-2A) THERAPY IS SIGNIFICANTLY ASSOCIATED WITH POST-TREATMENT RESPONSE IN HBEAG-NEGATIVE GENOTYPE D PATIENTS (2011) (5)
Lamivudine prophylaxis prevents hepatitis b reactivation in HBsAg-negative/anti-HBc-positive patients undergoing Rituximab-based chemotherapy for non–hodgkin's B cell lymphoma (2015) (4)
Effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients: Results of the Italian cohort of a post-marketing observational study. (2020) (4)
OC.09.6: GENETIC VARIATION IN IL28B POLYMORPHISM MAY PREDICT HBSAG CLEARANCE IN GENOTYPE D, HBEAG NEGATIVE PATIENTS TREATED WITH INTERFERON ALFA (2011) (4)
Nasal Glioma (Encephalochoristoma Nasofrontalis) Report of a Case (1964) (4)
777 INCIDENCE AND CLINICAL CONSEQUENCES OF REDUCED TUBULAR PHOSPHATE RE-ABSORPTION (TmPO4/GFR) IN NAÏVE CHRONIC HEPATITIS B PATIENTS TREATED WITH TENOFOVIR: A TWO-YEAR FIELD STUDY (2013) (4)
Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: a single-center prospective 3 year study (2018) (4)
Serum procollagen type III peptide levels in patients with acute viral hepatitis (1988) (4)
Hepatitis D – how is the fight against this foe going? (2019) (4)
Proteasome dysfunction as a reversible defect underlying virus-specific CD8 cell exhaustion in chronic hepatitis B (2017) (4)
CHANGES IN LIVER STIFFNESS DURING ENTECAVIR THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B (2009) (4)
Hepatitis B virus treatment: Which patients should be treated with nucleos(t)ide analogue? (2013) (4)
P1089 ADD-ON THERAPY WITH ENTECAVIR PLUS TENOFOVIR DUE TO VIRAL RESISTANCE OR PARTIAL RESPONSES FOLLOWED BY MONOTHERAPY IN CHB-PATIENTS: FINAL RESULTS FROM AN INTERNATIONAL MULTICENTRE STUDY (2014) (4)
Failure of adefovir 20 mg to improve suboptimal response in lamivudine‐resistant hepatitis B patients treated with adefovir 10 mg and lamivudine (2008) (4)
Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study (2022) (4)
An easy-to-use baseline scoring system to predict response to peginterferon alfa-2a in patients with chronic hepatitis B in resource-limited settings (2018) (4)
Contrast imaging techniques to diagnose hepatocellular carcinoma in cirrhotics outside regular surveillance. (2019) (4)
How Durable Is Functional Cure (Hepatitis B Surface Antigen Loss) in Patients With Chronic Hepatitis B Treated With Current Antivirals? (2020) (4)
524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS (2012) (4)
[57] 3 YEARS OF ADEFOVIR AND LAMIVUDINE COMBINATION THERAPY MINIMIZES THE RISK OF GENOTYPIC RESISTANCE TO ADV IN LAM RESISTANT PATIENTS (2007) (4)
Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy. (2021) (4)
Hepatitis C virus-induced glomerular disease and posterior reversible encephalopathy syndrome after liver transplant: Case report and literature review. (2019) (4)
Circulating cell‐free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients (2020) (4)
Cost analysis of a long‐term randomized controlled study in biliary duct‐to‐duct anastomotic stricture after liver transplantation (2021) (4)
Bulevirtide for patients with compensated chronic hepatitis delta: A review. (2022) (4)
Italian Migrants Study: an HCV and HBV Micro-Elimination Pilot Project (2021) (3)
Long-term outcome of patients with HBeAg-negative chronic hepatitis B treated with a 24-month course of interferon alfa (2001) (3)
Safety and Effectiveness Using 8 Weeks of Glecaprevir/Pibrentasvir in HCV-Infected Treatment-Naïve Patients with Compensated Cirrhosis: The CREST Study (2022) (3)
PS-184-Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: A meta-analysis (2019) (3)
Allelic inhibition of displacement activity: a simplified one tube allele-specific PCR for evaluation of ITPA polymorphisms. (2013) (3)
Long-term Outcomes in Patients with HBV Treated with Antiviral Agents (2018) (3)
1020 SAFETY AND EFFICACY OF ENTECAVIR AND TENOFOVIR COMBINATION-THERAPY IN HEPATITIS B PATIENTS WITH PREVIOUS TREATMENT FAILURES. AN INTERNATIONAL MULTICENTER COHORT STUDY (2010) (3)
Hbv-Related Liver Disease in Renal Insufficiency: Successful Antiviral Therapy with Entecavir (2011) (3)
FRI-212-HBV RNA can be detected more frequently than HBcrAg but decreases during long term treatment with nucleos (t)ide analogues up to 14 years in patients with HBeAg negative chronic hepatitis B (2019) (3)
Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in chronic hepatitis B, HBeAg-negative, genotype D patients fully suppressed on nucleot(s)ide analogues treatment: HERMES Study Interim Analysis (2015) (3)
382 CHANGES IN LIVER STIFFNESS DURING ENTECAVIR THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B (2009) (3)
Long-term lamivudine therapy improves child-pugh score in patients with hepatitis B-related cirrhosis (2000) (3)
FRI-376-Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival (2018) (3)
Worse outcome in younger adult renal graft recipients with HCV infection. An 8‐year prospective study (2000) (3)
A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B (2018) (3)
Reshape and secure HCC managing during COVID‐19 pandemic: A single centre analysis of four periods in 2020 versus 2019 (2021) (3)
P0655 : Lamivudine prophylaxis prevents hepatitis B reactivation in HBsAg-negative/anti-HBc-positive patients undergoing Rituximab-based chemotherapy for non-Hodgkin's B cell lymphoma (2015) (3)
Hepatitis B Virus Guide (2004) (3)
Treatment of 320 genotype 3 cirrhotic patients with 12 weeks Sofosbuvir/Velpatasvir with or without ribavirin: real life experience from Italy (2019) (3)
AISF position paper on HCV in immunocompromised patients (2019) (3)
Towards a Functional Cure for Hepatitis B Virus: A 2022 Update on New Antiviral Strategies (2022) (3)
Screening of esophagogastric varices: Performance of the “Expanded Baveno VI criteria” and the “platelet 150/MELD 6” strategy in all etiology compensated advanced chronic liver disease (2018) (3)
Progressive decline of HBsAg titers in longterm virological responders to nucleos(t)ide analogue therapy for chronic hepatitis B (2008) (2)
Integrated efficacy analysis of 24-week data from two phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg or 10 mg dose level for treatment of chronic hepatitis delta (2022) (2)
The course of anti-HBE/HBV-DNA positive chronic liver disease during long term lamivudine treatment (2003) (2)
Dual proteotoxic stress accelerates liver injury via activation of p62‐Nrf2 (2021) (2)
The Effect of Cytological Screening on Cervical Neoplasia in the Italian Province of Varese (1992) (2)
PROSPECTIVE STUDY OF DYSPLASTIC NODULES IN CIRRHOSIS: CORRELATION WITH CT VASCULAR PATTERN, HISTOLOGY AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (2009) (2)
HLA DPB1 rs9277535 polymorphism strongly predicts HBsAg clearance in interferon treated genotype D HBeAg-negative patients with chronic hepatitis B (2015) (2)
756 SERUM HBsAg DECLINE IS FASTER THAN PREVIOUSLY ESTIMATED IN LONG-TERM NUC RESPONDERS WITH LOW TREATMENT-INDUCED HBsAg LEVELS (2013) (2)
Natural History of Chronic Hepatitis B and Hepatocellular Carcinoma (2007) (2)
761 COMPARISON OF SERUM HBsAg DECLINES DURING TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN DIFFERENT CHRONIC HEPATITIS B (CHB) SUB-POPULATIONS (2013) (2)
[Direct-acting antiviral agents, hepatitis C and dialysis: an update]. (2018) (2)
Bulevirtide monotherapy for 48 Weeks in hdv patients with compensated cirrhosis and clinically significant portal hypertension. (2022) (2)
Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study (2020) (2)
Low risk of hepatitis B virus reactivation in HBsAg negative, anti-HBc positive carriers undergoing rituximab for rheumatoid arthritis (2014) (2)
RISK SCORE FOR HEPATOCELLULAR CARCINOMA IN CAUCASIANS WITH CHRONIC HEPATITIS B UNDER 5-YEAR ENTECAVIR OR TENOFOVIR THERAPY (2015) (2)
T-11 5-year entecavir in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC (2013) (2)
Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B (2021) (2)
Risk and outcome of hepatitis B virus (HBV) reactivation during chronic hepatitis C treatment with direct-acting antivirals (DAAs) in patients with HCV-related advanced fibrosis: A single-center experience (2018) (2)
The renal adenocarcinoma: epidemiological, clinical, pathological and cultural considerations based on 117 cases. (1984) (2)
Letter: does the IFNL4 gene discovery really provide a causal role for the IL28B haplotype blocks? (2014) (2)
Genetic variation in FCER1A predicts peginterferon alfa‐2a‐induced hepatitis B surface antigen clearance in East Asian patients with chronic hepatitis B (2019) (2)
Off-therapy cure of hepatitis delta after 3 years of bulevirtide monotherapy in a patient with compensated advanced cirrhosis (2022) (2)
Real-world clinical practice outcomes in hepatitis C-infected patients with psychiatric and substance use disorders treated with glecaprevir/pibrentasvir for 8 or 12 weeks: a pooled analysis across nine countries (2020) (2)
[Preliminary clinical correlations with the receptor state determined by histochemical method in primary breast tumors and secondary lesions]. (1985) (2)
A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results (2020) (2)
Safety and efficacy of tenofovir alafenamide in geriatric patients with chronic hepatitis B: experience from four ongoing phase 2 and phase 3 clinical trials (2020) (2)
Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro (2023) (2)
THU-151-Real-world effectiveness and safety of glecaprevir plus pibrentasvir in HCV: A multi-country analysis of postmarketing observational studies (2019) (2)
Assessing spleen stiffness by point shear‐wave elastography: Is it feasible and reproducible in patients with chronic liver disease? Is it useful to predict portal hypertension? (2019) (2)
OC.03.2 ENTECAVIR FOR NUC-NAÏVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: LONG-TERM EFFECTIVENESS FROM A LARGE MULTICENTER COHORT STUDY IN 376 PATIENTS (2010) (2)
Low body mass index (BMI) predicts discordance between transient elastography (TE) and liver biopsy (LB) assessment of liver fibrosis (2007) (2)
Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B (2020) (2)
THU-221-Xpert HBV VL, simplifying HBV viral load testing and disease management (2019) (2)
THU-131-Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: A real-life study from the NAVIGATORE Lombardia and Veneto Networks (2019) (2)
SAT-130-Incidence and outcome of portal vein thrombosis in 817 HBV and HCV compensated cirrhotic patients under antiviral treatment: a single center longitudinal study (2019) (2)
Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers (2020) (2)
Editorial: good news to patients with thalassaemia—HCV clearance made easy with direct‐acting antivirals (2017) (2)
Extended survival of patients with persistently suppressed hepatitis B transplanted for hepatocellular carcinoma (2015) (2)
Incidence and predictors of de novo hepatocellular carcinoma in HCV cirrhotic patients treated with direct-acting antivirals: A single-center prospective 3-year study (2018) (2)
545 DECLINE OF BONE MINERAL DENSITY DURING LONG-TERM NUCLEOS(T)IDE ANALOG THERAPY: A LONGITUDINAL COHORT STUDY OF 135 PATIENTS WITH CHRONIC HEPATITIS B (2012) (2)
Letter: do interferon lambda 3 polymorphisms predict the outcome of interferon therapy in hepatitis B infection? Authors' reply (2014) (2)
Is there any need for new, long-acting nucleos(t)ide analogues for the treatment of hepatitis B infection? (2021) (2)
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real‐Life Cohort Study (2021) (2)
916 ENTECAVIR IS AN EFFECTIVE TREATMENT FOR NUC-NAIVE CHRONIC HEPATITIS B PATIENTS IN CLINICAL PRACTICE: 48-WEEK DATA FROM A LARGE MULTICENTER COHORT STUDY (2009) (2)
IMPACT OF IFN ON PROGRESSION OF LIVER DISEASE IN HEPATITIS B “E” ANTIGEN (HBEAG) NEGATIVE CHRONIC HEPATITIS B (CHB) PATIENTS: A LONG TERM ITALIAN MULTICENTER A.I.S.F. STUDY. (2005) (2)
A Genotype-Specific Baseline Score to Predict Post-Treatment Response to Peginterferon Alfa-2a in HBeAg-Positive Patients with Hepatitis B Virus Genotype B or C Infection (2016) (2)
7 Clinical events during long term lamivudine treatment in anti-HBe/HBV-DNA positive chronic liver diseases (2003) (2)
Incidence of YMDD mutants, hepatocellular carcinoma and hepatic decompensation in patients with HBV-related cirrhosis treated long-term with lamivudine monotherapy (2001) (2)
Treatment of Non-Alcoholic Steatosis: Preclinical Study of a New Nutraceutical Multitarget Formulation (2020) (2)
[Correlations between receptor state and various clinico-morphological parameters: evaluation of circa 2000 cases of breast tumors]. (1985) (2)
499 No evidence for ADV resistance in HBeAg-negative lamivudine resistant patients treated with lamivudine-adefovir combination for 3 years (2006) (2)
Combination of CLIF-OF and CCI predicts survival in patients with cirrhosis and COVID-19 (2020) (1)
794 PROSPECTIVE STUDY OF DYSPLASTIC NODULES IN CIRRHOSIS: CORRELATION WITH CT VASCULAR PATTERN, HISTOLOGY AND DEVELOPMENT OF HEPATOCELLULAR CARCINOMA (2009) (1)
Outbreak of Acute Hepatitis A involving young men in Lombardy region, Italy: Risk factors, clinical and virological characteristics (2018) (1)
912 PROGRESSIVE DECLINE OF HBsAg TITERS IN LONG- TERM VIROLOGICAL RESPONDERS TO NUCLEOS(T)IDE ANALOGUE THERAPY FOR CHRONIC HEPATITIS B (2009) (1)
Entecavir monotherapy improves renal function in patients developing renal side effects during long-term tenofovir treatment without compromising virological response: A multicenter real-life study in 103 patients (2017) (1)
P.04.5 THE COURSE OF BONE MINERAL DENSITY IN PATIENTS WITH CHRONIC HEPATITIS B LONG TERM TREATED WITH NUCLEOS(T)IDE ANALOGS: A LONGITUDINAL COHORT STUDY (2012) (1)
T cell and humoral immune response to multiple SARS-CoV-2 variants including omicron (B1.1.529) after two doses of COVID-19 vaccine in patients with cirrhosis and liver diseases requiring immunosuppression: data from the EASL COVID-Hep network (2022) (1)
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV‐infected patients treated in a real‐life setting (2020) (1)
Ribavirin as a beneficial treatment option for hepatitis C virusassociated glomerular disease (2020) (1)
Commentary: absolute and relative contraindications to pegylated‐interferon or ribavirin in the US general patient population with chronic hepatitis C (2013) (1)
The impact of sustained virological response (SVR) on the criteria used to rule out high risk esophageal varices (HRV) in HCV-related compensated advanced chronic liver disease (cACLD) (2019) (1)
Letter: long‐term safety of nucleoside and nucleotide analogues in HBV‐monoinfected patients – authors’ reply (2016) (1)
Safety and effectiveness of Regorafenib in recurrent HCC after liver transplantation and progression on Sorafenib: a real-life multicentre study (2019) (1)
Efficacy and safety of Elbasvir/Grazoprevir in a large real-life cohort of HCV-infected patients (2019) (1)
Genetic variations in PD-1 and STAT4 genes do not predict off-treatment functional cure in IFN treated genotype D, HBeAg-negative patients with chronic hepatitis B (2017) (1)
[Applications of multiple morphological methods for the determination of receptor status in breast tumors]. (1987) (1)
IDDF2019-ABS-0169 A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results (2019) (1)
Fogging IBD Management: An Unusual Case of IBD Flare-up During the COVID-19 Outbreak (2020) (1)
[Papillary hidradenoma of the vulva: case reports and review]. (1978) (1)
Current Management of HBV Antiviral Drug Resistance (2011) (1)
Polymorphism AGT2 (rs4762) is involved in the development of dermatologic events: Proof-of-concept in hepatocellular carcinoma patients treated with sorafenib (2022) (1)
Genetic Variation in FCER1A Gene Predicts Sustained HBsAg Clearance in East-Asian Patients Treated with Pegylated Interferon Alfa-2a (40kd): The “Peg-Be-Yond” Study (2016) (1)
Hesitancy toward the Full COVID-19 Vaccination among Kidney, Liver and Lung Transplant Recipients in Italy (2022) (1)
Detecticn of hepatitis B virus (HBV) DNA in formalin-fixed. Paraffin-embedded liver tissue by polymerase chain reaction (1990) (1)
753 NUCLEOS(T)IDE ANALOGUES CAN BE SAFELY DISCONTINUED IN CHRONIC HEPATITIS B PATIENTS ACHIEVING HBSAG SEROCLEARANCE (2011) (1)
Validation of the EASL 2017 HBV Clinical Practice Guidelines criteria for switching patients long-term treated with Tenofovir Difumarate to Entecavir or Tenofovir Alafenamide in a real-life setting (2018) (1)
Effectiveness, safety and T-cell activation profiles of long-term Myrcludex B treatment in two patients with HDV related compensated cirrhosis (2019) (1)
P0647 : Proactive dose adjustments are necessary in many ADV-experienced patients treated with TDF monotherapy for 5 years: A prospective cohort study in 320 patients (2015) (1)
Regorafenib improves survival after sorafenib in patients with recurrent HCC after liver transplantation (2021) (1)
F-35 Nucleos(t)ide analogues can be safely discontinued in chronic hepatitis B patients achieving HBsAg seroclearance (2011) (1)
Hepatitis C virus (HCV) antibodies in alcoholics (1990) (1)
Twenty-four months combination therapy with adefovir dipivoxil and lamivudine in lamivudine resistano patients with HBeAg-negative chronic hepatitis B (2005) (1)
[Congenital atresia of the tricuspid valve. Clinical and anatomical observations apropos of a case]. (1959) (1)
Interferon Therapy in Hepatitis B e Antigen-Negative Chronic Hepatitis B : reply (2003) (1)
Long-term outcome of hepatitis B in lamivudine-resistant cirrhotic patients (2002) (1)
Implementation of hcv screening in the 1969-1989 birth-cohort undergoing covid-19 vaccination: a pivotal study in Italy (2022) (1)
Management of lamivudine resistance: An overview (2008) (1)
NUCLEOS(T)IDE ANALOG THERAPY OF CHRONIC HEPATITIS B AND LIVER CANCER RISK REDUCTION: BETTER NUCLEOTIDES THAN NUCLEOSIDES? (2019) (1)
Focus on Very Late Hepatocellular Carcinoma Recurring After Liver Transplantation: A Case Report and Literature Review. (2019) (1)
744 TREATMENT OF MULTIRESISTANT HBV PATIENTS WITH ENTECAVIR PLUS TENOFOVIR. 2 YEARS SAFETY AND EFFICACY ANALYSIS. AN INTERNATIONAL MULTICENTER COHORT STUDY (2011) (1)
389 LOW RISK OF HEPATOCELLULAR CARCINOMA RECURRENCE AFTER LIVER TRANSPLANTATION: A 3-YEAR FOLLOW-UP STUDY IN 78 PATIENTS WITH CHRONIC HEPATITIS B (2008) (1)
Acute kidney injury and chronic kidney disease after liver transplant: A retrospective observational study. (2021) (1)
[Primary carcinoma in situ of the vagina. (Case report and review of literature)]. (1967) (1)
The impact of surveillance on hepatocellular carcinoma. Detection and survival of 417 patients with compensated cirrhosis: a 12-year prospective cohort study (2002) (1)
Cytology and hormonal receptors in breast cancer (1987) (1)
Improvement of clinical parameters in HDV patients with advanced compensated cirrhosis treated with Bulevirtide monotherapy for 48 weeks (2023) (1)
P0750 : Enhanced liver fibrosis (ELF) test does not predict residual cirrhosis after a sustained virological response to hepatitis C treatment (2015) (1)
O113 : HLA DPB1 rs9277535 polymorphism strongly predicts HBsAg clearance in IFN treated genotype D HBeAg-negative patients with chronic hepatitis B (2015) (1)
PS-054-Quantitative antibodies against hepatitis B core antigen differ in NUC suppressed caucasian HbeAG-negative patients compared to patients who achieved either “NUC induced” or “spontaneous” functional cure of HBV (2019) (1)
Editorial: similar risk of hepatocellar carcinoma in chronic hepatitis B patients treated with tenofovir or entecavir—new clues from Europe (2021) (1)
Prognostic Value of Histochemical Evaluation of Steroid Binding Sites in Breast Tumors (1988) (1)
EILF-Italian migrants study: An HCV and HBV micro elimination pilot project (2021) (1)
Bulevirtide‐based treatment strategies for chronic hepatitis delta: A review (2023) (1)
Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct acting antivirals: a 3-year study in 509 patients (2019) (1)
P1059 PORTAL HYPERTENSION BUT NOT HCC RISK IS ATTENUATED IN COMPENSATED CIRRHOTICS FOLLOWING 10 YEARS OF TREATMENT WITH NUCLEOS(T)IDE ANALOGS (2014) (1)
[Polyomavirus infections of the urinary tract. Cytologic and ultrastructural features]. (1994) (1)
Multimodal and sequential treatment for hepatocellular carcinoma: How “real-life” complies with international recommendations (2018) (1)
Effectiveness and safety of sofosbuvir-based direct-acting antiviral combinations in HCV-2 and HCV-3 kidney transplant recipients. (2019) (1)
SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with DAAs: a prospective multi-centric Italian study (2018) (1)
Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks (2023) (1)
Portal hypertension but not HCC risk is attenuated in compensated cirrhotics following 10 years of treatment with nucleos(t)ide analogs (2014) (1)
OC-30 Incidence and clinical consequences of reduced tubular phosphate re-absorption in naïve CHB patients treated with tenofovir: a two-year field study (2013) (1)
High rates of tenofovir dose adjustments are required in Adefovir experienced patients with chronic hepatitis B: A 4-year prospective study in 320 patients (2014) (1)
RESIST-HCV Criteria to Monitor Progression of Low-Risk Esophageal Varices in Patients With Compensated Cirrhosis After HCV Eradication: The SIMPLE Study (2022) (1)
A genetic risk score predicts de novo hepatocellular carcinoma in hepatits c cirrhotic patients treated with direct-acting antivirals (2020) (1)
Is it time to refine HCC surveillance strategies in HCV cured patients? (2022) (1)
The CCR5 and CXCR3 Pathways in Hepatitis C Virus Liver Transplanted Recipients Treated by a Direct Antiviral Agent Regimen: Informative Kinetics Profiles. (2021) (1)
THU-141-Efficacy and safety of elbasvir/grazoprevir in a large real-life cohort of HCV-infected patients (2019) (1)
Sarcopenia predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib (2018) (1)
[Leiomyosarcomas and leiomyomas of the small intestine. Case reports and review of the literature]. (1969) (1)
Reproducibility and diagnostic accuracy of pocket-sized ultrasound devices in ruling out compensated cirrhosis of mixed etiology (2022) (1)
Proactive dose adjustments are necessary in many ADV-experienced patients treated with TDF monotherapy for 5 years: A prospective cohort study in 320 patients (2015) (1)
The natural history of hepatitis C in renal allograft recipients: A 5-year prospective study in 443 patients (1995) (1)
Nucleos(t)ide analogs-based chemoprevention of liver cancer in hepatitis B patients: effective, yet in search of optimization. (2013) (1)
THU-166-Treatment of 320 genotype 3 cirrhotic patients with 12 weeks of sofosbuvir/velpatasvir with or without ribavirin: Real life experience from Italy (2019) (1)
Hepatitis Delta Virus Infection Increases the Efficacy of HBV-Specific T Cell-Based Therapies (2020) (1)
[Neurocutaneous melanosis]. (1987) (1)
Algorithms using noninvasive tests can accurately identify patients with advanced fibrosis due to NASH: data from the STELLAR clinical trials (2019) (1)
27 Rescue treatment with adefovir dipivoxil for lamivudine resistant patients pre- and post- liver transplantation (2003) (1)
3 years of adefovir and lamivudine combination therapy minimizes the risk of genotypic resistance to ADV in lamivudine resistant patients (2007) (1)
THU-180-Treatment of genotype 3 HCV infection in the large real-life “Navigatore Lombardia” multicentre cohort: Results from three different regimens (2019) (1)
Epidemiology, features and outcome of patients transplanted for hepatocellular carcinoma in the last decade: a single-center experience (2020) (0)
A genetic risk score predicts de novo hepatocellular carcinoma in hepatitis C cirrotic patients treated with direct-acting antivirals (2020) (0)
Impact of von Willebrand factor/ADAMTS-13 on the pro-coagulant imbalance detected in cirrhosis (2017) (0)
[Lipoma of the stomach associated with carcinoma. Description of two cases]. (1959) (0)
Entecavir or tenofovir monotherapy prevents hepatitis B virus recurrence in liver transplant recipients: a 5-year follow-up study after hepatitis B immunoglobulin withdrawal (2017) (0)
[Primary lymphoma of the kidney. Description of a case and brief review of the literature]. (1992) (0)
The Impact of Antiviral Treatment of Hepatitis B Virus after Kidney Transplant and the Latest Insights (2023) (0)
An Unprecedented Challenge: The North Italian Gastroenterologist Response to COVID-19 (2021) (0)
Predictors of hepatocellular recurrence after liver transplant in Hepatitis C patients: A ten-years single center cohort (2018) (0)
FRI-256-Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage (2019) (0)
OC.12.2 RESIST CRITERIA: A BIOCHEMICAL ALGORITHM TO REDUCE THE NUMBER OF UNNECESSARY UPPER ENDOSCOPIES FOR THE EVALUATION OF PORTAL HYPERTENSION IN COMPENSATED HBVCIRRHOTIC PATIENTS (2023) (0)
[ON THE GENESIS OF ADRENAL HEMORRHAGES IN ADULTS]. (1964) (0)
IDDF2021-ABS-0078 Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD) (2021) (0)
Forecasting liver disease burden based on a real life cohort of the linked to care patients in Italy. Does the ‘underwater portion of the iceberg’ matter to reach the WHO HCV eliminating goals in the high HCV prevalent countries? (2018) (0)
High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis (2018) (0)
Long-term outcome of patients with HBaAg-negative chronic hepatitis B treated with a 24-month course of interferon alta (2001) (0)
[Leiomyosarcoma of the bladder. Presentation of a case and review of the literature]. (1986) (0)
[INTRODUCTORY NOTE TO THE STUDY OF VASCULAR ALTERATIONS IN RADIODERMITIS]. (1965) (0)
Early recurrence of hepatocellular carcinoma after liver transplantation can be predicted by FDG-PET and microvascular invasion at explant pathology (2020) (0)
Serum levels of circulating DNA species can predict the development of hepatocellular carcinoma in chronic hepatitis B patients under long-term oral antiviral therapy (2020) (0)
Procoagulant imbalance in chronic hepatitis C and its relationship with cardiovascular and liver damage (2019) (0)
SAT-227-Clinical but not genetic variables predict the development of hepatocellular carcinoma in hepatitis C cirrhotic patients treated with direct-acting antivirals: A 3-year study in 509 patients (2019) (0)
Multi-country Viral Hepatitis COMmunity Screening, Vaccination, and Care (VH-COMSAVAC): Project outline (2023) (0)
The HSD17B13 rs6834314 variant is associated with liver stiffness measurement in untreated HCV-3 patients with cirrhosis (2020) (0)
768 LOW RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH CHRONIC HEPATITIS C AND CONCURRENT INACTIVE HEPATITIS B INFECTION TREATED WITH INTERFERON AND RIBAVIRIN (2008) (0)
Effectiveness and safety of bulevirtide monotherapy 2 mg/die in hdv patients with compensated cirrhosis and clinically significant portal hypertension (2022) (0)
Ultrasound guided paracentesis: A study on reproducibility and diagnostic accuracy of a Pocket-size Ultrasound Device (PUD) (2021) (0)
IL28B Polymorphisms in Interferon-Treated Patients with Chronic Hepatitis B (2013) (0)
Monitoring serum HBV-DNA during lamivudine therapy by quantitative PCR assay may predict development of YMDD mutants (2000) (0)
Evolution of HCV treatments with direct acting antivirals between 2014 and 2017 in 8637 HCV patients in a real world setting: A report from the Lombardia Network and Navigator Study Group (2018) (0)
[A case of neonatal acute leukemia]. (1970) (0)
Integrated safety analysis of 24-week data from three phase 2 and one phase 3 clinical trials of bulevirtide monotherapy given at 2 mg and 10 mg dose level for treatment of chronic hepatitis delta (2022) (0)
Acute kidney injury and chronic kidney disease after liver transplant: A retrospective observational study. (2022) (0)
Omicron SARS-CoV-2 variant outbreak in vaccinated liver transplant (LT) recipients in 2022: A large spread of infection, a mild disease (2023) (0)
Lamivudine treatment of chronic hepatitis B: evaluation of drug-resistance by the INNO-LiPA HBV DR (2001) (0)
Tenofovir Alafenamide improves proximal tubular markers in CHB patients long-term treated with Tenofovir Disoproxil Fumarate: A real-life study based on the EASL switching criteria (2021) (0)
Five years survival of 1112 patients with cancer of the breast: prognostic value of clinico-morphological parameters including the histochemically evaluated receptor status. An Italian cooperative study. (1991) (0)
Incidence and outcome of portal vein thrombosis in HCV cirrhotic patients treated with direct-acting antivirals: A single-center prospective 3-year study (2018) (0)
Regorafenib improves survival after sorafenib treatment in patients with recurrent hepatocellular carcinoma after liver transplantation, compared to best supportive care (2020) (0)
Application of transient elastography in chronic hepatitis B: authors’ reply (2011) (0)
Genetic variants do not predict the development of hepatocellular carcinoma in cross-sectional and longitudinal studies including caucasian compensated HBV cirrhotics treated with NUC for 10 years (2020) (0)
Lamivudine for chronic hepatitis B (2000) (0)
251 Increased expression of vascular endothelial growth factor and its receptor in hepatocellular carcinoma and extra-tumoral cirrhotic tissues (2004) (0)
F-17 Serum HBsAg decline is faster than previously estimated in long-term NUC responders with low treatment-induced HBsAg levels (2013) (0)
Emergence and takeover of pre-core mutants are associated to anti-HBE seroconversion and hepatitis remission in HBeAg chronic hepatitis B (1993) (0)
T06.01.5 DIAGNOSTIC ACCURACY OF A POCKET-SIZE ULTRASOUND DEVICE IN IDENTIFYING LIVER SURFACE NODULARITY FOR FIBROSIS STAGING IN CHRONIC LIVER DISEASE (2020) (0)
Development and validation of an artificial intelligence PIVKA-II-based model for the prediction of hepatocellular carcinoma development in patients with HCV-related cirrhosis successfully treated with direct-acting antivirals (2022) (0)
Rapid Communication Detection ofHepatitis BVirus DNAinFormalin- fixed, Paraffin-embedded Liver Tissue bythe Polymerase Chain Reaction (1990) (0)
THU-134-Clinical and virological characteristics of patients with chronic hepatitis C and failure to voxilaprevir/velpatasvir/sofosbuvir treatment (2019) (0)
Validation of the Baveno VI criteria for screening of esophageal varices in patients with metabolic and alcohol related compensated advanced chronic liver disease (2017) (0)
FRI-474-AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma (2019) (0)
[Loosening of total hip prosthesis]. (1990) (0)
Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis (2023) (0)
P.103 No evidence for ADV resistance in HBeAg-negative lamivudine resistant patients treated with lamivudine-adefovir combination for 3 years (2006) (0)
The international autoimmune hepatitis group scoring system in patients with chronic hepatitis C and serum autoantibodies undergoing interferon/ribavirin therapy : a prospective validation study (2006) (0)
[Preservation of anatomical specimens in plastic bags]. (1961) (0)
Serum markers for extracellular matrix components in the diagnosis of alcoholic hepatitis (1990) (0)
IDDF2019-ABS-0212 Real-world effectiveness and safety of glecaprevir/pibrentasvir in adults with chronic hepatitis C virus infection: a meta-analysis (2019) (0)
[Receptor status of cytologic material in primary and secondary breast tumors]. (1987) (0)
[Solitary lung and associated multiple malformations: case contribution and review of the literarure]. (1965) (0)
Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B? Authors' reply (2022) (0)
Carvedilol to reduce the risk of decompensation in patients with compensated cirrhosis: really needed also in patients with HCV cured or HBV suppressed viral cirrhosis? (2023) (0)
[CONGENITAL ATRESIA OF THE BILIARY TRACT]. (1963) (0)
F-13 Switching to tenofovir is safe in most CHB patients with a reduced glomerular filtration rate due to previous exposure to adefovir dipivoxil (2013) (0)
THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naive to direct acting antivirals: Particular focus on natural resistance (2019) (0)
Prevalence and impact on post-transplant outcome of sarcopenia among patients with cirrhosis on waiting-list for liver transplantation: Preliminary data from an Italian single center experience (2021) (0)
Long-term effective oral therapy could spare endoscopic surveillance of esophageal varices in HBV compensated cirrhotics: a 10-year study (2021) (0)
[Presence of aspergillar conidiophores in 2 cases of pulmonary mycosis]. (1961) (0)
Nucleos(t)ide Analogue Based Therapy and Management of Patients (2016) (0)
1072 A five-year cohort study of patients with dual infection with HBV and HCV (2003) (0)
Corrigendum to ‘An international genome-wide meta-analysis of primary biliary cholangitis: Novel risk loci and candidate drugs’ [J Hepatol 2021;75(3):572–581] (2021) (0)
NATURAL HISTORY OF HEPATITIS B AND/OR C IN RENAL GRAFT RECIPIENTS (2004) (0)
[Activity and results of the campaign for early diagnosis of tumors of the breast]. (1971) (0)
[Round table: Histochemical evaluation of receptor status in breast cancer. Introduction]. (1985) (0)
[A case of acute neonatal leukemia]. (1970) (0)
477 High rates of hepatitis B virus reverse seroconversion in anti-HBc carriers undergoing allogeneic bone marrow transplantation (2006) (0)
Hepatitis D: Looking Back, Looking Forward, Seeing the Reward and the Promise (2023) (0)
Serum markers for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment (2017) (0)
Immunomodulatory effects of the large fluctuations in IFN-γ and IL-8 accompanying hepatic flares in anti-HBe chronic HBV patients. (2005) (0)
Effectiveness and safety of DAA treatment for recurrent hepatitis C after liver transplantation: The NAVIGATOR Lombardia-Veneto network (2018) (0)
VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen (2020) (0)
Clinical Evaluation of Plasma Separation Cards as a Tool to Collect, Store, and Test Blood Samples for Hepatitis B and C Serological Markers. (2021) (0)
Natural history of HCC developing in HBV-related cirrhotic patients undergoing antiviral treatment with nucleo(s)tide analogues (2007) (0)
[Automation in histology: evaluation of a device for automatic covering of histologic slides]. (1994) (0)
Correction to: Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis (2020) (0)
Validation of the EASL 2017 HBV clinical practice guidelines criteria for switching patients long-term treated with Tenofovir difumarate to Entecavir or Tenofovir alafenamide in a real life setting (2018) (0)
Chronic hepatitis B patients developing tubular dysfunction during long-term tenofovir treatment can be successfully and safely rescued by entecavir (2014) (0)
Trends in chronic Hepatitis B virus infection in Italy over a 10-year period: clues from the nationwide PITER and MASTER cohorts towards elimination. (2023) (0)
Hepatocellular carcinoma developing in European patients with prolonged HBV suppression: Biological and clinical features, and outcome (2016) (0)
Excellent effectiveness of direct-acting antivirals for HCV treatment in patients with cirrhosis: Analysis of 3345 patients from the Lombardia Network (2018) (0)
Impaired renal function but high sustained virological response (SVR) rates in hepatitis C virus (HCV) elderly treated with direct-acting antivirals (DAA): A report from the Lombardy Network (2018) (0)
Incidence of liver-related events in 647 HCV cirrhotics treated with DAA: A 5-year single center study (2021) (0)
Sa1522 EFFICACY AND SAFETY OF SWITCHING TO TENOFOVIR ALAFENAMIDE IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B PATIENTS WITH RENAL IMPAIRMENT: WEEK 24 RESULTS FROM A PHASE 2 OPEN-LABEL STUDY (2020) (0)
Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts (2022) (0)
Cirrhosis regression does not prevent hepatocellular carcinoma in patients with a sustained virological response to IFN (2017) (0)
Correlation between HBV core-related antigen and the new quantitative IGG anti-core in treated caucasian HBeAg-negative patients and inactive carriers with and without a functional cure (2020) (0)
A 3-Year Course Of Bulevirtide Monotherapy May Cure Hdv Infection In Cirrhotics. (2023) (0)
Multimodal and sequential treatmente for hepatocellular carcinoma: how “real-life” complies with international recommendations (2018) (0)
F-42 OptiB Italian multicenter prospective study on tenofovir in suboptimal responders to ADV or ADV/LAM treatment: 96 weeks results on efficacy and tolerance (2011) (0)
FRI-197-Prediction of elastographic reversion of cirrhosis after 5 years of entecavir or tenofovir disoproxil fumarate therapy in caucasian chronic hepatitis B patients (2019) (0)
[The other cytology (author's transl)]. (1978) (0)
Cytoplasmic foreign material in liver and spleen. An iatrogenic complication of haemodialysis. (1983) (0)
Renal transplantation - clinical studies - 1 (2009) (0)
[Cavernous angioma of the spleen: observation of 2 cases]. (1980) (0)
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohort. (2023) (0)
Safety and effectiveness of DAA treatment and clinical outcomes of HCV liver transplanted patients with recurrent hepatitis C infection: A single center 3-year study from Italy (2018) (0)
Bulevirtide 2 mg/day monotherapy in patients with chronic hepatitis delta with or without cirrhosis: a multicenter european cohort real-life study (2022) (0)
Serum Markers for early diagnosis of hepatocellular carcinoma in hepatitis C cirrhotic patients with sustained virological response to direct-acting antivirals treatment (2017) (0)
Factor VIII/protein C and not ADAMTS13/VWF:Ag ratio is a prognostic risk factor for patients with cirrhosis and low MELD score (2020) (0)
SAT-132-Incidence and prognostic factors of de novo development/worsening of esophageal varices in HCV-related compensated advanced chronic liver disease after sustained virological response achieved by direct antiviral agents (2019) (0)
P.051 Hepatitis B virus reverse seroconversion in allogeneic hematopoietic stem cell transplantation (2006) (0)
IFNL4 polymorphisms predict sustained response and HBsAg clearance in interferon treated HBeAg negative chronic hepatitis B patients (2015) (0)
The development of hepatolocellular carcinoma is not predicted by genetic variants in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 10 years (2019) (0)
CS3.3 INDEPENDENT PREDICTORS OF DISCORDANCE BETWEEN TRANSIENT ELASTOGRAPHY (TE) AND LIVER BIOPSY (2008) (0)
[Papillary carcinoma in thyroglossal duct cyst remnant: review of the literature and presentation of a clinical case]. (1990) (0)
732 EFFICACY AND TOLERANCE OF TENOFOVIR IN SUBOPTIMAL RESPONDERS TO ADV OR ADV/LAM TREATMENT: 96 WEEKS RESULTS OF THE OPTIB ITALIAN MULTICENTER PROSPECTIVE OPEN LABEL STUDY (2011) (0)
An Easy-to-Use Baseline Score to Predict Response to Peginterferon Alfa-2a in Patients with Chronic Hepatitis B in Resource-Limited Settings (2016) (0)
Implementation of HCV screening in the 1969–1989 birth-cohort undergoing COVID-19 vaccination: a pivotal study in Italy (2022) (0)
[Diagnostic significance of the liver scintigraphy in chronic liver diseases : comparison with liver needle biopsy]. (1975) (0)
[Neurilemmoma of the vulva. (Case report and review of literature)]. (1967) (0)
Fate of HDV-specific CD8+ T cells during bulevirtide monotherapy in patients with chronic hepatitis delta (2022) (0)
187 INDEPENDENT INFLUENCERS OF TRANSIENT ELASTOGRAPHY ASSESSMENT OF LIVER FIBROSIS IN HEPATITIS B AND HEPATITIS C PATIENTS (2009) (0)
[Perforated gastro-duodenal ulcer in newborn infants with multiple abnormalities]. (1966) (0)
[Occult carcinoma of the breast with axillary and bone lymph node metastasis]. (1986) (0)
Maintained HBV suppression in lamivudine-resistant patients treated with adefovir and lamivudine combination: A 4- year cohort study in 63 patients (2008) (0)
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis. (2018) (0)
Forecasting liver disease burden (2018) (0)
A prospective study of alfafetoprotein (AFP) mRNA in peripheral blood of cirrhotics as a predictor of hepatocellular carcinoma (HCC) (2000) (0)
Minimal increases of alpha-fetoprotein above the normal value strongly predict HCC development in compensated Caucasian HBV cirrhotics treated by entecavir or tenofovir: a 7-year longitudinal cohort study in 225 patients (2017) (0)
Related articles (2012) (0)
Hepatitis B virus reverse seroconversion in allogeneic hematopoietic stem cell transplantation (2006) (0)
Have liver transplant recipients displayed COVID-19 vaccine hesitancy? (2021) (0)
OC-15High rates of renal tubular damage in HBV monoinfected patients long-term treated with tenofovir: A cross-sectional, single center, real-life study in 414 patients (2017) (0)
Eight cases of mycotic oesophagitis in new-born infants submitted to treatment with antibiotics. (1959) (0)
[Suggested changes in current laws dealing with the activities of pathological anatomy departments]. (1976) (0)
[Method and results of the colpocytological campaign in the Busto Arsizio Section of the CPLCTV]. (1971) (0)
Excellent long-term virological and clinical response in HDV compensated cirrhotics treated with high dose Bulevirtide beyond 2.5 years: A case series (2021) (0)
Worse outcome in younger adult renal graft recipients with HCV infection. An 8-year prospective study (2000) (0)
[Epidemiology of breast tumors in a city of 80,000 inhabitants during the past 30 years]. (1982) (0)
STAT4 variants increase liver fibrosis risk in chronic hepatitis B through impaired STAT4- dependent NK cell IFN-γ production (0)
PAGE-B score is simpler and has similar predictive performance with the new Asian hepatocellular carcinoma risk scores in Caucasian chronic hepatitis B patients treated with long-term entecavir or tenofovir disoproxil fumarate therapy (2020) (0)
No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta. (2023) (0)
Clinical presentation and etiological spectrum of idiopathic non-cirrhotic portal hypertension (INCPH): data from the Italian Registry (2019) (0)
A variant in the MICA gene is associated with liver fibrosis progression in chronic hepatitis C through TGF-β1 dependent mechanisms (2019) (0)
Metabolic dysfunction outperforms ultrasonographic steatosis to stratify hepatocellular carcinoma risk in patients with advanced hepatitis C cured with direct-acting antivirals. (2023) (0)
Risk factors for post-banding ulcer bleeding in cirrhotic patients undergoing elective esophageal varices band ligation (2021) (0)
Divergent patterns of hbv-rna and hbcrag levels in untreated chronic hepatitis delta: a large european cross-sectional study (2022) (0)
Healthcare resource utilization in treatment-naïve patients with compensated cirrhosis receiving 8-weeks’ glecaprevir/ pibrentasvir stratified by drug use and socioeconomic status: a retrospective chart review (2022) (0)
448 Rescue treatment with adefovir dipivoxil in lamivudine resistant patients with chronic hepatitis B (2004) (0)
PIVKA_II a useful biomarker for hepatocellular carcinoma in caucasian HCV cirrhotic patients treated with direct-acting antivirals (2020) (0)
Treatment with bulevirtide improves patient-reported outcomes in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks (2022) (0)
Correction to: Real-World Outcomes in Historically Underserved Patients with Chronic Hepatitis C Infection Treated with Glecaprevir/Pibrentasvir (2021) (0)
283 INDEPENDENT PREDICTORS OF DISCORDANCE BETWEEN TRANSIENT ELASTOGRAPHY (TE) AND LIVER BIOPSY (LB) (2008) (0)
S1070 A Phase 3 Study Comparing Switching: Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Final Week 96 Results (2020) (0)
Characterization of baseline factors associated with treatment outcome in HCV-infected patients naive to direct acting antivirals: particular focus on natural resistance (2019) (0)
[Peritonitis caused by perforation of sigmoid carcinoid]. (1968) (0)
Risk and outcome of hepatitis B virus reactivation during chronic hepatitis C treatment with direct-acting antivirals in patients with HCV-related advanced fibrosis: a single-center experience (2018) (0)
Combined approach for embolization of otherwise unmanageable gastric varices (2021) (0)
Epidemiological, virological and clinical profile of HBsAg positive individuals in Italian hospital settings: interim results of the HBV/HDV PITER cohort (2022) (0)
Most patients with advanced cirrhosis treated with bulevirtide monotherapy have a non-monophasic HDV RNA decline patterns: an interim kinetic analysis of real-life setting (2022) (0)
T-17 Add-on Peg-IFN improves HBsAg kinetics in HBeAg-negative patients long-term fully suppressed by nucleos(t)ide analogs (2013) (0)
Excellent 5-years survival for HBV cirrhotic patients developing a hepatocellular carcinoma during long-term analogs treatment (2018) (0)
PA.102 VERY EARLY ADD-ON ADEFOVIR THERAPY IN PATIENTS WITH SUB-OPTIMAL VIROLOGICAL RESPONSE TO LAMIVUDINE (2008) (0)
Incidence and risk factors of esophagogastric varices bleeding in cirrhotic patients with advanced hepatocellular carcinoma treated with lenvatinib (2023) (0)
Reply to: "Clinical relevance of dynamic risk assessment for developing hepatocellular carcinoma during prolonged antiviral therapy". (2020) (0)
From add-on cobination therapy to mono-therapy in treatment experienced CHB patients with viral resistance or partial responses: Results from an international mulicentre cohort study (2013) (0)
Editorial: the role for PIVKA‐II measurement after HCV elimination by direct‐acting antivirals in terms of prediction of hepatocellular carcinoma—authors' reply (2021) (0)
PP22 EPIDEMIOLOGY OF HEPATITIS B VIRUS GENOTYPES IN ITALY: STUDY OF A PEDIATRIC POPULATION (2009) (0)
P661 APRI AND FIB-4 VS HISTOLOGY IN CHB PATIENTS IN TENOFOVIR DISOPROXIL FUMARATE (TDF) CLINICAL TRIALS (2014) (0)
[Epidemiological survey of thyroid pathology in the Lombardy region 1977-1979]. (1982) (0)
Book Reviews – Buchbesprechungen – Livres Nouveaux (1967) (0)
Effectiveness and safety of Sofosbuvir/Velpatasvir/Voxilaprevir for retreatment of chronic hepatitis C patients with a previous failure to direct-acting antivirals: a real-life study from the Navigatore Lombardia and Veneto Networks (2019) (0)
TLL1 variants do not predict the development of de-novo hepatocellular carcinoma in HCV cirrhotics treated with IFN-free DAA-based regimens (2018) (0)
[Aspergillus endocariditis on a cardiac valve prosthesis. A problem to be solved]. (1979) (0)
PA.103 LOW RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH CHRONIC HEPATITIS C AND CONCURRENT INACTIVE HEPATITIS B INFECTION TREATED WITH INTERFERON AND RIBAVIRIN (2008) (0)
Viral kinetics in hbeag positive and negative patients with HBV-related cirrhosis treated long-term with lamivudine (2001) (0)
Chemokine changes during direct antiviral agents (DAA) therapy in patients with HCV infection or reinfection after liver transplantation: preliminary insights on their possible correlates (2019) (0)
SAT-131-The impact of sustained virological response on the criteria used to rule out high risk esophageal varices in HCV-related compensated advanced chronic liver disease (2019) (0)
Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data (2023) (0)
SVR is the strongest predictor of occurrence and recurrence of hepatocellular carcinoma in HCV cirrhotic patients after treatment with direct acting antivirals: A prospective multicenter Italian study (2018) (0)
Cancer of the Breast (2018) (0)
Eight-weeks of glecaprevir/pibrentasvir is well tolerated and yields high sustained virological response in HCV-infected treatment-naive patients with compensated cirrhosis: the CREST study (2022) (0)
Reply to: "Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B". (2020) (0)
Incidence and prognostic factors of “de novo” development/worsening of esophageal varices in HCV-related chronic advanced liver disease after sustained virologic response achieved by direct oral antiviral agents (2019) (0)
THU-133-Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience (2019) (0)
T.N.18 THE HBV-SPECIFIC T CELL FUNCTION CAN BE RECONSTITUTED IN CHRONIC HBV INFECTION: IMPLICATIONS FOR IMMUNE THERAPIES (2010) (0)
1058 Real World Effectiveness and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Infection: A Meta-Analysis (2019) (0)
PS-079-HDV co-infection modifies the immunoproteasome profile of HBV infected hepatocytes leading to increased CD8 T-cell recognition: Implication for immunotherapy (2019) (0)
High rates of renal tubular damage in HBV monoinfected patients long-term treated with Tenofovir: a cross-sectional, single center, real-life study in 414 patients (2017) (0)
405 – Efficacy and Safety Results 48 Weeks After Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) Vs Continued Tdf Treatment in Virologically-Suppressed Patients with Chronic Hepatitis B (CHB) (2019) (0)
[Epidemiologic study of thyroid pathology in Italy 1977-1979, Introduction]. (1982) (0)
Changes in bone mineral density during monotherapy with tenofovir disoproxil fumarate: a 6-year real life longitudinal cohort study in chronic hepatitis B caucasian patients (2020) (0)
COMPARISON OF ENHANCED LIVER FIBROSIS TEST AND TRANSIENT ELASTOGRAPHY FOR THE NON-INVASIVE ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HEPATITIS B (2011) (0)
Reply letter. (2021) (0)
Baseline clinical features but not TLL1 variants predicts HCC onset in Caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years (2018) (0)
Do you need to account for baseline viral load when assessing the relative efficacy of interventions for treatment naïve hbeag positive chronic hepatitis b (chb) patients? results from unadjusted and adjusted network meta-analyses (nma) (2013) (0)
190 GRAFT DYSFUNCTION (GD) IN HBV RECURRENCEFREE RECIPIENTS IS ASSOCIATED WITH SERUM AUTOANTIBODIES REACTIVITY (2008) (0)
Genotypic analysis of YMDD locus of HBV in patients responding to lamivudine monotherapy (2003) (0)
TM6SF2, MBOAT7 and PNPLA3 genotypes in patients with untreated HCV chronic hepatitis and alcohol intake (2017) (0)
Transient elastography predicts response to prolonged therapy with a nucleoside analog in patients with chronic hepatitis B (2009) (0)
Non-invasive tests to predict liver-related events in a single-center cohort of 486 HCV cirrhotic patients treated with DAA (2021) (0)
Randomised phase 2 study (JADE) of the HBV capsid assembly modulator JNJ-56136379 with or without a nucleos(t)ide analogue in patients with chronic hepatitis B infection (2023) (0)
[Presence of parasites in the appendix: A study on 6760 appendectomies (author's transl)]. (1980) (0)
THU-128-Renal safety in 3,264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study (2019) (0)
[Not Available]. (2013) (0)
Humoral, cellular, clinical responses and safety to SARS-CoV-2 messanger RNA vaccines in patients with compensated and decompensated cirrhosis: a long-term single center prospective study (2022) (0)
Diabetes and number of metabolic risk factors influence liver disease severity in patients with non-alcoholic fatty liver disease (2022) (0)
FRI-183-A phase 3 study comparing switching from tenofovir disoproxil fumarate to tenofovir alafenamide with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results (2019) (0)
The composition of HBsAg during peginterferon-alfa2a treatment can predict treatment response in HBV/HDV-coinfection (2020) (0)
The long-term risk and outcome of non-neoplastic portal vein thrombosis developing in compesated caucasian HBV cirrhotics treated with Tenofovir or Entecavir (2018) (0)
Incidence and outcome of portal vein thrombosis in 817 HBV and HCV cirrhotic patients under antiviral treatment: a single center longitudinal study (2019) (0)
IFN impact on liver disease progression in HBeAg negative chronic hepatitis B (CHB): a long-term italian multicenter AISF study (2005) (0)
P187 INNATE ANTIVIRAL RESPONSES IN HBeAg NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (CH-B) UNDER LONG-TERM NUCLEOS(T)IDE ANALOGUE (NUC) TREATMENT: IMPLICATIONS FOR FUTURE IMMUNE THERAPIES (2014) (0)
SAT0258 Low Risk of Hepatitis B Virus Surface Antigen Seroreversion in Hbsag Negative, Anti-Hbc Positive Carriers Undergoing Rituximab for Rheumatoid Arthritis (2014) (0)
[Gastric hemangioma: a cause of digestive hemorrhage]. (1987) (0)
Reply: (2013) (0)
[Genital tuberculosis and adenocarcinoma of the endometrium]. (1982) (0)
Extension of Bulevirtide monotherapy to 72 weeks in HDV patients with compensated cirrhosis: Efficacy and safety from the italian multicenter study (HEP4Di) (2023) (0)
Usefulness of longitudinal assessment of AFP in DAA cured HCV cirrhotic patients to predict the developmente of HCC (2022) (0)
Moderate and severe renal impairment in European CHB patients treated with TDF or ETV: a 7-year retrospective cohort study in 490 patients (on behalf of the ReCoRd investigators group) (2018) (0)
P658 LOW RISK OF HEPATITIS B VIRUS REACTIVATION IN HBsAg NEGATIVE, ANTI-HBc POSITIVE CARRIERS UNDERGOING RITUXIMAB FOR RHEUMATOID ARTHRITIS (2014) (0)
Coagulation balance and liver damage in non-cirrhotic patients with chronic hepatitis C after eradication by Direct-acting Antiviral Agents (DAAs) (2021) (0)
[Presence of binding sites for steroid hormones in urothelial tumors]. (1987) (0)
Controlled attenuation parameter in primary biliary cholangitis: a cross-sectional analysis (2022) (0)
Reply to: "Challenges associated with the roll-out of HCC surveillance in sub-Saharan Africa - the case of Uganda". (2020) (0)
[Breast carcinoma: the positivity of steroid hormone receptors, morphologically demonstrated with 2 different methods, changes the significance of various conventional prognostic factors]. (1992) (0)
Long-term endoscopic surveillance in HBV compensated cirrhotic patients treated with Tenofovir or Entecavir for 11 years. (2023) (0)
Clinical features predictive of cirrhosis in a large cohort of patients with chronic hepatitis delta infection- Insights from the D-LIVR trial (2022) (0)
Entecavir for lamivudine-naïve patients with chronic hepatitis B (2008) (0)
Safety and efficacy of up to 76 weeks 10 mg (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis (2020) (0)
Transient elastography (TE) accurately predicts liver fibrosis stage in patients with chronic Hepatitis B (2008) (0)
A new algorithm shows superior ability to discriminate liver fibrosis stages in chronic hepatitis C (2021) (0)
Does Nucleos(t)ide (NUC) Analogs Therapy in Hepatitis B Impact the Incidence of Liver Cancer? (2015) (0)
Deregulated intracellular pathways define novel molecular targets for HBV-specific CD8 T cell reconstitution in chronic hepatitis B. (2023) (0)
The combination of IFN-lambda-4 and HLA-DPB1 polymorphisms accurately predict HBsAg loss in IFN treated genotype D HBeAg-negative patients with chronic hepatitis B (2016) (0)
Reply (2003) (0)
[Cytological aspects, critical considerations and epidemiological studies of tumors of the endometrium observed during cytological mass screening from 1962 to 1977 at the Busto Arsizio Hospital]. (1979) (0)
P23 Comparison of enhanced liver fibrosis test and transient elastography for the non-invasive assessment of liver fibrosis in chronic hepatitis B (2011) (0)
P.1.95: DUAL CUT-OFF ELASTOGRAPHY TO ASSESS LIVER FIBROSIS IN CHRONIC HEPATITIS B: A COHORT STUDY WITH INTERNAL VALIDATION (2011) (0)
Comparative performance analysis between manual and automatic RNA extraction to quantify HDV RNA by RoboGene 2.0 kit in untreated and bulevirtide-treated HDV patients (2022) (0)
Procoagulant imbalance in patients with non-cirrhotic chronic hepatitis C (CHC) improves six months after eradication with direct-acting antiviral agents (DAAs) and likely correlates with liver fibrosis (2020) (0)
Epidemiology, features and outcomes of patients transplanted for hepatocellular carcinoma in the last decade: a single center experience (2020) (0)
Diagnostic accuracy of a pocket-size ultrasound device in identifying liver surface nodularity for fibrosis staging in chronic liver disease (2020) (0)
Real-world effectiveness and safety of glecaprevir/ pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis Graphical (2020) (0)
769 FROM COMBINATION-THERAPY TO MONO-THERAPY IN TREATMENT EXPERIENCED CHB PATIENTS WITH VIRAL RESISTANCE OR PARTIAL RESPONSES: FIRST RESULTS OF AN INTERNATIONAL MULTICENTER COHORT STUDY (2013) (0)
AGT gene polymorphisms predict early dose modification of sorafenib for dermatological adverse events: towards tailored medicine for patients with hepatocellular carcinoma (2019) (0)
Changes of AFP and PIVKA-II levels during DAA treatment and their predictive value for early diagnosis of HCC in HCV cirrhotic patients with SVR to DAA treatment (2018) (0)
Clinical and genetic predictors of HCC occuring in caucasian compensated HBV cirrhotics treated by Entecavir or Tenofovir for 8 years (2018) (0)
Impact of von Willebrand factor and ADAMTS-13 on the pro-coagulant imbalance of patients with cirrhosis (2017) (0)
IDDF2020-ABS-0060 Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF (2020) (0)
Rescue treatment with adefovir dipivoxil for lamivudine resistant patients pre- and post- liver transplantation (2003) (0)
RESIST Criteria: A biochemical algorithm to reduce the number of unnecessary upper endoscopies for the evaluation of portal hypertension in compensated HBV-cirrhotic patients (2023) (0)
FRI-473-Safety and effectiveness of regorafenib in recurrent HCC after liver transplantation and progression on sorafenib: A real-life multicentre study (2019) (0)
Switching tdf treated patients to taf is a safe and effective strategy even in difficult-to-manage elderly patients with hbv-related cirrhosis and significant comorbidities: a real-life prospective study (2022) (0)
IDDF2021-ABS-0080 96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity (2021) (0)
Strong correlation between HBsAg, ALT and HDV-RNA levels in patients with chronic hepatitis D. Results of phase 3 D-LIVR study. (2022) (0)
A prospective study of lens culinaris agglutinin-reactive alpha-fetoprotein as a predictor of hepatocellular carcinoma in cirrhotics (2000) (0)
Identification of circulating microRNAs predictive of HCC in DAA-cured HCV-related cirrhosis (2020) (0)
O-12 : Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) in Virally Suppressed Chronic Hepatitis B (CHB) Patients with Moderate or Severe Renal Impairment, or in End-Stage Renal Disease (ESRD) Patients on Hemodialysis (HD): Week 2 (2020) (0)
20 Liver expression of estrogen receptors alpha and beta correlates with aetiology and presentation of hepatocellular carcinoma (2003) (0)
Temporal trends of access to DAAs treatments for HCV in the Navigatore-Lombardia network: Evolution of AIFA criteria, DAA regimens and patient features (2018) (0)
Incidence of gastric carcinoma, histologically documented in the years 1972-1973 in 35 Italian laboratories of anatomical pathology. (1975) (0)
PA65 ENTECAVIR TREATMENT IN A CASE OF SEVERE ACUTE HEPATITIS B (2010) (0)
Humoral, cellular, clinical responses and safety of two doses of SARS-CoV-2 Messenger RNA vaccine in patients with compensated and decompensated cirrhosis: a long-term single center prospective study (2022) (0)
Minimal increases of alpha-fetoprotein strongly predict HCC development in caucasian compensated HBV cirrhotics treated by entecavir or tenofovir: A 7-year longitudinal cohort study in 225 patients (2017) (0)
Safety and efficacy of up to 76 weeks 10 mg/day (high dose) bulevirtide monotherapy in compensated cirrhotics with delta hepatitis (2020) (0)
Issue Cover (2020) (0)
The long-term course of hepatitis C — Related cirrhosis (2001) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Pietro Lampertico?

Pietro Lampertico is affiliated with the following schools:

University of Milan
ETH Zurich
University of Zurich

Pietro Lampertico's Academic­Influence.com Rankings

Why Is Pietro Lampertico Influential?

Pietro Lampertico's Published Works

Published Works

What Schools Are Affiliated With Pietro Lampertico?

Pietro Lampertico's AcademicInfluence.com Rankings